What's transthyretin amyloidosis?
Transthyretin amyloidosis develops when misfolded transthyretin protein deposits in the body as amyloid. In the heart it leads to a progressive infiltrative cardiomyopathy, with heart failure and conduction abnormalities.
| Features mapped | 5 |
|---|---|
| Treatments mapped | 1 |
| Published sources | 5 |
| Last reviewed | 2026-08-04 |
Signs and symptoms
Sensorimotor neuropathy
Peripheral nerve damage (neuropathy) is one of the two cardinal features of transthyretin amyloidosis, producing sensory and motor symptoms.
Constrictive median neuropathy
Transthyretin amyloidosis often first appears as carpal tunnel syndrome, sometimes years before other symptoms.
Restrictive cardiomyopathy
The heart is commonly affected in transthyretin amyloidosis, typically as a restrictive cardiomyopathy in which the heart muscle becomes stiff.
Congestive heart failure
Heart failure can develop in transthyretin amyloidosis as amyloid builds up in the heart.
Nephropathy
Amyloid can deposit in the kidneys in transthyretin amyloidosis, affecting kidney function (nephropathy).
Treatment and management
What the research describes, not a recommendation. Treatment decisions belong with your clinician.
This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.
tafamidis
Tafamidis is used to treat transthyretin amyloid cardiomyopathy, where it lowers the risk of death and hospitalization.
Used to help with: Restrictive cardiomyopathy.
“Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and tafamidis has proven efficacy in reducing mortality and hospitalizations in this population.”
How to read the evidence labels
Where this comes from
This guide is built from 5 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.
Take it further
Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.